LY333531;LY-333531;LY 333531

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酰胺类
• 英文名称: LY333531;LY-333531;LY 333531
• 英文别名: 18-[(dimethylamino)methyl]-17-oxa-4,14,21-triazahexacyclo[19.6.1.17,14.02,6.08,13.022,27]nonacosa-1(28),2(6),7(29),8,10,12,22,24,26-nonaene-3,5-dione
• 化学式: C₂₈H₂₈N₄O₃
• 分子量: 468.5
• InChiKey: ZCBUQCWBWNUWSU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  35
• 可旋转键数：
  2
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  68.5
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Method of manufacturing ruboxistarin
  申请人：Zentiva, k.s.

  公开号：EP2181999A1

  公开（公告）日：2010-05-05

  Method of manufacturing ruboxistaurin, comprising the steps of preparation of L-2-deoxyribose 1-cyano-3,4-dibenzoate, followed by deprotection to 1-cyano L-2-deoxyribose, oxidative cleaving to (S)-4-hydroxy-2-(2-hydroxy-ethoxy)-butyronitrile and transformation to the methanesulfonic acid (S)-3-cyano-3-(2-methanesulfonyloxyethoxy)-propyl ester, then coupling with 1-substituted-3,4-bis(3-indolyl)maleimide leading to 9H,18H-5,21:12,17-dimethenodibenzo[e,k]pyrrolo[3,4-h][1,4,13] oxadiazacyclohexadecine-18,20(19H)-dione, 6,7,10,11-tetrahydro-19-substituted-9(S)-cyano, followed by methylation of the amino group and deprotection forming 5,21:12,17-dimetheno-9H-dibenzo[e,k]furo[3,4-h][1,4,13]oxadiazacyclohexadecine-18,20-dione, 6,7,10,11-tetrahydro-9-[(dimethylamino)methyl]-, (S)- (9CI), and the final step consisting of imido preparation to form ruboxistaurin.

  生产鲁博西他林的方法，包括以下步骤：制备L-2-去氧核糖-1-氰-3,4-二苯甲酸酯，然后去保护成为1-氰基L-2-去氧核糖，氧化断裂成(S)-4-羟基-2-(2-羟基乙氧基)-丁腈，并转化为甲磺酸(S)-3-氰基-3-(2-甲磺酰氧乙氧基)-丙基酯，然后与1-取代-3,4-双(3-吲哚基)马来酰亚胺偶联，得到9H,18H-5,21:12,17-二甲烯二苯并[e,k]吡咯并[3,4-h][1,4,13]噁二氮杂环十六烷-18,20(19H)-二酮，6,7,10,11-四氢-19-取代-9(S)-氰基，然后甲基化氨基团并去保护，形成5,21:12,17-二甲烯-9H-二苯并[e,k]呋喃[3,4-h][1,4,13]噁二氮杂环十六烷-18,20-二酮，6,7,10,11-四氢-9-[(二甲氨基)甲基]-，(S)- (9CI)，最后一步是制备亚砜以形成鲁博西他林。
• Soft tissue implants and anti-scarring agents
  申请人：Hunter L. William

  公开号：US20050142162A1

  公开（公告）日：2005-06-30

  Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

  软组织植入物（例如乳房、胸肌、下巴、面部、唇部和鼻部植入物）与抗瘢痕剂结合使用，以抑制动物体内植入物放置时可能发生的瘢痕形成。
• Compounds for immunopotentiation
  申请人：Valiante Nicholas

  公开号：US20100226931A1

  公开（公告）日：2010-09-09

  Methods of stimulating an immune response and treating patients responsive thereto with 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-diones, staurosporine analogs, derivatized pyridazines, chromen-4-ones, indolinones, quinazolines, nucleoside analogs, and other small molecules are disclosed. In a preferred embodiment benzopyrimidine derivatives such as ZD-6474, MLN-518, lapatinib, gefitinib or erlotinib are used.

  本发明公开了刺激免疫反应和治疗对3,4-二（1H-吲哚-3-基）-1H-吡咯-2,5-二酮，链霉菌素类似物，衍生的吡啶并嗪，香豆素-4-酮，吲哚酮，喹唑啉，核苷类似物和其他小分子具有响应性的患者。在一种优选实施方式中，使用苯并嘧啶衍生物，例如ZD-6474，MLN-518，拉帕替尼，吉非替尼或厄洛替尼。
• Implantable sensors and implantable pumps and anti-scarring agents
  申请人：Hunter L. William

  公开号：US20050152946A1

  公开（公告）日：2005-07-14

  Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

  用于与组织接触的泵和传感器与抗疤痕剂（如细胞周期抑制剂）结合使用，以抑制在动物体内植入泵和传感器时可能出现的疤痕。
• Polymer compositions and methods for their use
  申请人：Hunter L. William

  公开号：US20050178395A1

  公开（公告）日：2005-08-18

  Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

  包含抗纤维化剂和/或聚合物的组合物可用于各种医疗应用，包括预防手术粘连、治疗炎症性关节炎、治疗疤痕和瘢痕疙瘩、治疗血管疾病以及预防软骨流失。